Zai Lab gains European orphan drug designation
Zai Lab (NASDAQ:ZLAB) has received European orphan drug designation for its antibody-drug conjugate targeting 375,000 annual lung cancer cases.
Zai Lab (NASDAQ:ZLAB) has received European orphan drug designation for its antibody-drug conjugate targeting 375,000 annual lung cancer cases.
Nebius (NASDAQ:NBIS) completed its corporate acquisition of model optimization developer Eigen AI on June 10, 2026.
Vince Holding (NASDAQ:VNCE) reported a 10.5% increase in first-quarter net sales to $64 million, driven by expansion across its direct-to-consumer and wholesale segments.
Edgewise Therapeutics (NASDAQ:EWTX) reported positive 12-week Phase 2 data evaluating its investigational heart disease treatment called EDG-7500.
Invivyd (NASDAQ:IVVD) completed enrollment in its Phase 3 LIBERTY trial to evaluate a potential COVID-19 prevention option.
Robinhood Markets (NASDAQ:HOOD) announced a 10% workforce reduction to maintain its long-term corporate agility and efficiency.
Prestige Consumer Healthcare (NYSE:PBH) closed its acquisition of the Breathe Right brand for $1.045 billion.
Parsons (NYSE:PSN) secured design and construction oversight contracts for the estimated $1.1–$1.4 billion John A. Blatnik Bridge replacement project.
InterDigital (NASDAQ:IDCC) secured a patent infringement injunction against Disney (NYSE:DIS) across 11 European Union countries for its video technology.
ITT (NYSE:ITT) signed a definitive agreement to acquire Aerospace Contacts LLC for a purchase price of $31 million.
Space Exploration Technologies (NASDAQ:SPCX) and Anysphere (“Cursor”) announced they have entered into an agreement and plan of merger.
Olin (NYSE:OLN) and Huntsman (NYSE:HUN) agreed to an all-stock merger to form a $12.5 billion chemical company.